These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 39059991)
1. Biomarker identification of medullary thyroid carcinoma from gene expression profiles considering without-treatment and with-treatment studies-A bioinformatics approach. Loganathan T; George Priya Doss C Adv Protein Chem Struct Biol; 2024; 142():367-396. PubMed ID: 39059991 [TBL] [Abstract][Full Text] [Related]
2. Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma. Alqahtani T; Kumarasamy VM; Huczyński A; Sun D Int J Oncol; 2020 Jan; 56(1):348-358. PubMed ID: 31746350 [TBL] [Abstract][Full Text] [Related]
4. [ Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622 [TBL] [Abstract][Full Text] [Related]
5. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer. Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667 [TBL] [Abstract][Full Text] [Related]
6. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine. Kumarasamy VM; Shin YJ; White J; Sun D BMC Cancer; 2015 Aug; 15():599. PubMed ID: 26307103 [TBL] [Abstract][Full Text] [Related]
7. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative. Kumarasamy VM; Sun D Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409 [TBL] [Abstract][Full Text] [Related]
8. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation. Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037 [TBL] [Abstract][Full Text] [Related]
9. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit. Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586 [TBL] [Abstract][Full Text] [Related]
10. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations. Barletta JA; Nosé V; Sadow PM Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588 [TBL] [Abstract][Full Text] [Related]
11. Thyroid C-Cell Biology and Oncogenic Transformation. Cote GJ; Grubbs EG; Hofmann MC Recent Results Cancer Res; 2015; 204():1-39. PubMed ID: 26494382 [TBL] [Abstract][Full Text] [Related]
12. Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in Mancikova V; Montero-Conde C; Perales-Paton J; Fernandez A; Santacana M; Jodkowska K; Inglada-Pérez L; Castelblanco E; Borrego S; Encinas M; Matias-Guiu X; Fraga M; Robledo M Clin Cancer Res; 2017 Mar; 23(5):1334-1345. PubMed ID: 27620278 [No Abstract] [Full Text] [Related]
13. Two GEO MicroRNA Expression Profile Based High-Throughput Screen to Identify MicroRNA-31-3p Regulating Growth of Medullary Thyroid Carcinoma Cell by Targeting RASA2. Jiang M; Shi X; Zhu H; Wei W; Li J Med Sci Monit; 2019 Jul; 25():5170-5180. PubMed ID: 31298226 [TBL] [Abstract][Full Text] [Related]
14. Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy. Vitale G; Dicitore A; Messina E; Sciammarella C; Faggiano A; Colao A Recent Pat Anticancer Drug Discov; 2016; 11(3):275-82. PubMed ID: 27306881 [TBL] [Abstract][Full Text] [Related]
15. Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations. Oczko-Wojciechowska M; Swierniak M; Krajewska J; Kowalska M; Kowal M; Stokowy T; Wojtas B; Rusinek D; Pawlaczek A; Czarniecka A; Szpak-Ulczok S; Gawlik T; Chmielik E; Tyszkiewicz T; Nikiel B; Lange D; Jarzab M; Wiench M; Jarzab B Sci Rep; 2017 Feb; 7():42074. PubMed ID: 28181547 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Heilmann AM; Subbiah V; Wang K; Sun JX; Elvin JA; Chmielecki J; Sherman SI; Murthy R; Busaidy NL; Subbiah I; Yelensky R; Nangia C; Vergilio JA; Khan SA; Erlich RL; Lipson D; Ross JS; Miller VA; Shah MH; Ali SM; Stephens PJ Oncology; 2016; 90(6):339-46. PubMed ID: 27207748 [TBL] [Abstract][Full Text] [Related]
18. Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer. Lopergolo A; Perrone R; Tortoreto M; Doria F; Beretta GL; Zuco V; Freccero M; Borrello MG; Lanzi C; Richter SN; Zaffaroni N; Folini M Oncotarget; 2016 Aug; 7(31):49649-49663. PubMed ID: 27351133 [TBL] [Abstract][Full Text] [Related]
19. Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms. Ceolin L; Siqueira DR; Romitti M; Ferreira CV; Maia AL Int J Mol Sci; 2012; 13(1):221-39. PubMed ID: 22312249 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Mian C; Pennelli G; Fassan M; Balistreri M; Barollo S; Cavedon E; Galuppini F; Pizzi M; Vianello F; Pelizzo MR; Girelli ME; Rugge M; Opocher G Thyroid; 2012 Sep; 22(9):890-6. PubMed ID: 22747440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]